Royalty Pharma to pay up to $950 million for royalties from Amgen's lung cancer drug

Retrieved on: 2025-08-25 22:37:25

Tags for this article:

Click the tags to see associated articles and topics

Royalty Pharma to pay up to $950 million for royalties from Amgen's lung cancer drug. View article details on hiswai:

Excerpt

In 2022, it had bought royalty interests in Roche's lung cancer drug Gavreto for up to $340 million. Amgen's Imdelltra reduced the risk of death ...

Article found on: www.tradingview.com